STRO · Sutro Biopharma, Inc.
$25.12
+0.97 (+4.02%)
At close · Aug 7
Market Cap
$400.18M
Shares
16.57M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$24.15
Open$24.96
Day$23.62–25.90
52W$7.15–43.85
Avg vol 30d387K
Short int1.7M · 10.0% float · 4.5d
Short vol46%
Last earningsMay 27, 2026
DataJan 2020–Aug 2026
Filing10-Q · May 14
Up next
Next earnings call
Aug 26, 2026
Est · unconfirmed
· in 3 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.2 · calm
Equity put/call 0.60
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+15%
above
Price vs 50-day avg
−12%
below
RSI (14)
43
neutral
MACD trend
Positive
52-week position
46%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−19%
trailing
6-month return
+55%
trailing
YTD return
+109%
this year
Relative strength
+42%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $27 › 200d $21 — 50d above 200d
Institutional flow
Accumulating
20 of 78 funds reported for Jun 30 · net +102.4K sh shares · +8 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.97% of float · ▲ +21.4% MoM · 4.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
78 holders — mid 3-yr range
Squeeze score
61
elevated · 0–100
Fundamentals
Revenue growth
−26%
Y/Y
EPS growth
+24%
Y/Y
Free cash flow
$-178.8M
Balance sheet
$54.1M
net cash
Quant / Vol
risk profile
Volatility
90%
annualized · 1-yr
Max drawdown
−45%
past year
ATR
8.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+15%
Bullish
Price vs 50-day avg
−12%
Bearish
RSI (14)
43
Neutral
MACD trend
Positive
Bullish
52-week position
46%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $27 › 200d $21 — 50d above 200d
Institutional flow
Accumulating
20 of 78 funds reported for Jun 30 · net +102.4K sh shares · +8 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.97% of float · ▲ +21.4% MoM · 4.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
78 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $7
Now $24 · 46%
52-wk high $44
vs 200-day avg +15%
vs 50-day avg -12%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
STRO
this stock
Sutro Biopharma, Inc.
|
$400.18M | +108.7% | -25.7% | — | 10.0% |
|
ONC
BeOne Medicines Ltd.
|
$487.49B | +8.6% | +22179.2% | 749.6 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$122.68B | +6.8% | +46.2% | 28.2 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$79.49B | +0.3% | +20.8% | 19.1 | 3.4% |
|
ARGX
Argenx SE
|
$54.76B | +4.1% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| STRO | -2.7% | -19.5% | +54.6% | -0.1% | +108.7% |
| SPY | +3.6% | +2.2% | +12.8% | +2.9% | +12.7% |
| vs SPY | -6.3% | -21.7% | +41.8% | -3.0% | +96.0% |
Key facts
CIK
1382101
CUSIP
869367201
13F (30d)
18 filings
18 filers
Visit website
Investor relations